Core Insights - TGS has secured a 4D streamer contract in the Campos basin, offshore Brazil, with a survey scheduled for the second half of 2026 lasting approximately 75 days [1][2]. Company Overview - TGS is a leading provider of energy data and intelligence, offering advanced technology and solutions across the entire energy value chain [3]. - The company utilizes proprietary GeoStreamer technology and purpose-built Ramform vessels to deliver high-quality data for optimizing production in the energy sector [2][3]. Contract Details - The awarded contract is for an independent energy company in Brazil, emphasizing TGS's capability to maintain industry-leading acquisition efficiency [2]. - The mobilization of the Ramform vessel for the survey is planned for the latter half of 2026 [1].

Louvain-la-Neuve, Belgium, December 11, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with China Gold Irradiation (CGI), the largest high standard irradiation service company in China, to install a Rhodotron® in Jiaxing, Zhejiang Province, as a first step of the transition of China’s irradiation processing industry to a new stage of hig ...

Core Viewpoint - Roche has received CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring, establishing the broadest in-vitro diagnostics (IVD) menu for automated mass spectrometry platforms with 39 frequently tested targets [1][7]. Group 1: Product and Technology - The cobas® Mass Spec solution Ionify® reagent portfolio includes tests for therapeutic drug monitoring for immunosuppressants and antibiotics, as well as steroid hormones and vitamin D metabolites, enabling a transition to fully automated and standardized solutions [2][4]. - The high specificity, sensitivity, and accuracy of mass spectrometry are recognized as the diagnostic 'gold standard' for various clinical situations, making it accessible to routine laboratories through the cobas Mass Spec solution [4][7]. - The automated mass spectrometry platform reduces turnaround times and supports faster, standardized, high-quality care by replacing labor-intensive manual workflows [7]. Group 2: Market Availability and Regulatory Status - The cobas Mass Spec solution is currently available in selected markets accepting the CE mark, including the UK, Canada, and Japan, and has achieved "moderate complexity" categorization under CLIA in the US [3]. - Roche is actively working with regulatory authorities worldwide to expand the availability of its systems and assays [3]. Group 3: Future Developments - Roche is committed to expanding its mass spectrometry menu with additional assays, including the first panel for drugs of abuse testing and further therapeutic drug monitoring parameters in the coming years [2][7].

Core Viewpoint - Ontex Group NV has revised its full-year revenue growth expectations downward due to weaker-than-expected consumer demand, particularly affecting baby care sales in October and November [1][4]. Revenue Expectations - Ontex anticipates a high-single digit like-for-like revenue drop in the fourth quarter compared to the same period in 2024, contrasting with previous expectations of stable performance [2]. - The revenue decrease is expected to negatively impact margins, adjusted EBITDA, and free cash flow in the fourth quarter [2]. Operational Changes - New contracts that began delivery in the third quarter are now fully operational in Europe and North America, but at lower volumes than anticipated [3]. - Ontex is accelerating a €200 million efficiency improvement initiative across operations and SG&A over the next three years, with one-off implementation costs expected to remain below €40 million [3]. Financial Projections - Revenue is now expected to reduce by mid-single digit like-for-like, adjusted EBITDA is projected to be in the range of €175 to €180 million, representing a margin of around 10% [6]. - Free cash flow is anticipated to be around €(35) million, and the leverage ratio is expected to end at around 3.2x [6]. Management Commentary - The CEO of Ontex stated that the softening consumer demand, particularly for baby diapers, has led to the revision of the full-year outlook, despite progress in strategic portfolio and operational transformation [4].

November was characterised by growth in strategic loan products and term deposits, a decrease in the share of non-performing loans, and satisfactory profitability. The loan portfolio grew by 25 million euros during the month, reaching 2.6 billion euros by the end of November. Growth was driven by business loans, which increased by 33 million euros, and home loans, which grew by 14 million euros. The consumer loan portfolio decreased by 22 million euros. A significant part of this decline was due to the sale ...

Core Insights - The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medicines for rare hematologic diseases: Qfitlia for hemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura (aTTP) [1] - These approvals represent Sanofi's fourth and fifth approvals in China for the year, following Tzield and Sarclisa [1] Qfitlia Overview - Qfitlia is the first antithrombin-lowering therapy for routine prophylaxis in hemophilia patients aged 12 and older, including those with severe hemophilia A or B [2] - The approval is based on ATLAS phase 3 studies showing significant reductions in annualized bleeding rates (ABR) for patients treated with Qfitlia [3] - Qfitlia utilizes small-interfering RNA technology, allowing for low treatment frequency and subcutaneous administration [3][15] - Hemophilia affects over 40,000 individuals in China, highlighting the need for effective treatment options [3] Cablivi Overview - Cablivi is the first targeted therapy for treating aTTP in adults and adolescents aged 12 or older [4] - Approximately 2,700 patients are diagnosed with aTTP annually in China, with a mortality rate of up to 20% despite standard treatments [5] - Cablivi works by inhibiting the interaction between von Willebrand factor and platelets, thus preventing microthrombi formation [5][18] Market Impact - The approvals of Qfitlia and Cablivi expand Sanofi's rare hematology portfolio in China, addressing critical unmet needs in chronic bleeding disorders and acute clotting emergencies [6] - Sanofi's commitment to innovation is emphasized by these approvals, aiming to improve outcomes for patients with rare diseases [7] Clinical Results - Qfitlia demonstrated a 71% reduction in ABR for patients without inhibitors and a 73% reduction for patients with inhibitors compared to traditional treatments [9] - In the open-label extension study, nearly 80% of participants were on a regimen of six injections per year, with 94% achieving target AT levels [17]

Core Insights - EZVIZ is promoting its smart home products during the festive season, emphasizing joy and security for families in Southeast Asia as the year ends [1][3] Product Highlights - EZVIZ offers exclusive savings on its popular smart home camera collection, enhancing home security and connectivity [3] - The C6N Indoor Pan & Tilt Wi-Fi Camera features 360° pan-and-tilt control, motion detection, Smart IR night vision, and two-way talk capabilities [4] - The C90 Dual-Lens Outdoor Pan & Tilt Camera provides wide and detailed views with 2K⁺ resolution, color night vision, and smart notifications to differentiate between people and vehicles [5]

Core Points - Robex Resources Inc. has entered into an Amending Agreement with Predictive Discovery Limited and 9548-5991 Québec Inc. to amend the previously announced arrangement agreement for the acquisition of Robex Shares [2][4] - Under the Amended Agreement, Robex Shareholders will receive 7.862 Predictive Shares for each Robex Share, resulting in a post-transaction ownership of approximately 46.5% for former Robex Shareholders in the combined company [3][6] - The merger aims to create one of West Africa's leading gold producers, combining two significant projects with projected production exceeding 400,000 ounces annually by 2029 and combined resources of approximately 9.5 million ounces of gold [13][25] Amended Arrangement Agreement - The Amended Agreement was reached following a competing superior proposal received by Predictive, which was subsequently deemed not superior under the terms of the original Arrangement Agreement [4] - The transaction is expected to be accretive to shareholders, providing exposure to high-quality assets and potential index inclusion [6][13] - The deadline for Robex Shareholders to vote has been revised to December 29, 2025, with no further action required for those who have already voted [11][14] Shareholder Support - Major shareholders representing approximately 23.8% of outstanding Robex Shares have entered into amended voting agreements in support of the transaction [6][10] - The Robex Board has unanimously recommended that shareholders vote in favor of the Arrangement Resolution, supported by updated fairness opinions from financial advisors [9][8] Strategic Benefits - The merger combines two low-cost, advanced projects, Kiniero and Bankan, optimizing development and exploration efforts [13][6] - The combined company is positioned for enhanced market profile and liquidity, with potential inclusion in major indices such as ASX 200 and GDXJ [13][6] - Experienced leadership with proven expertise in the region will drive effective execution of the combined company's strategy [13][6]

Core Insights - Federal infrastructure spending and private-sector investments are driving growth in North American structural steel, with Bodor Laser's advanced solutions improving manufacturing efficiency and precision [1][4]. Company Overview - Bodor Laser offers integrated profile-processing solutions, including the U3000 and Hicut Fiber Laser Cutter, which enhance fabrication processes for manufacturers [1][3]. - The U3000 can process profiles, sheets, and tubes with a maximum length of 110.24 inches, allowing for multiple worktables to facilitate continuous operations [3]. - The Hicut is designed specifically for automated I-beam and H-beam fabrication, integrating various processes such as loading, hole-making, and cutting into a single automated cycle [3][4]. Technological Advancements - Bodor's solutions simplify complex workflows by unifying multiple processes, reducing positioning errors, and ensuring high accuracy in design reproduction [2][4]. - Features include rapid loading in under 20 seconds, intelligent zoning for workpiece grouping, and five-axis linkage for high-precision cuts [6][7]. Market Position - Bodor has maintained its position as a leader in global fiber-laser sales for six consecutive years, indicating strong market recognition and demand for its products [4][7]. - The company is expanding its service team and local spare-parts inventory in North America to better support manufacturers and meet regional demand [7].

Core Insights - EZVIZ is promoting its smart products during the festive season, emphasizing joy and security for families in Southeast Asia [1] - The company is offering exclusive savings on popular smart cameras, making smart living more accessible [2] Product Highlights - **H8c Outdoor Pan & Tilt Wi-Fi Camera**: Features 360-degree coverage, smart person detection, auto-tracking, and two-way communication, designed for all weather conditions [2] - **C6N G1 Indoor Outdoor Pan & Tilt Wi-Fi Camera**: Offers 4K video, 350° pan, and 85° tilt for comprehensive coverage, with smart motion detection and two-way audio [3] - **H7c Dual-Lens Indoor Pan & Tilt Wi-Fi Camera**: Combines a wide-angle fixed lens and a pan-and-tilt lens, includes loud-noise detection and smart human-shape alerts, with 2K+ video and color night vision [4] - **H9c Dual Lens Indoor Pan & Tilt Wi-Fi Camera**: Features a wide-angle lens and a pan-and-tilt lens, automatically tracking movement with 2K clarity and color night vision [5]